Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul;29(7):739.
doi: 10.1111/iju.14919. Epub 2022 Apr 27.

Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma

Takashi Kobayashi  1
Affiliations
Editorial

Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma

Takashi Kobayashi. Int J Urol. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Comment on

References

    1. Togashi K, Hatakeyama S, Yoneyama T et al. Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. Int. J. Urol. 2022; 29: 733–9. - PMC - PubMed
    1. Amatu A, Pani A, Patelli G et al. Impaired seroconversion after SARS‐CoV‐2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. Eur. J. Cancer 2022; 163: 16–25. - PMC - PubMed
    1. Funakoshi Y, Yakushijin K, Ohji G et al. Safety and immunogenicity of the COVID‐19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. J. Infect. Chemother. 2022; 28: 516–20. - PMC - PubMed
    1. Rottenberg Y, Grinshpun A, Ben‐Dov IZ, Oiknine Djian E, Wolf DG, Kadouri L. Assessment of response to a third dose of the SARS‐CoV‐2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. 2022; 8: 300–1. - PMC - PubMed
    1. Kobayashi T, Ito K, Kojima T et al. Pre‐pembrolizumab neutrophil‐to‐lymphocyte ratio (NLR) predicts the efficacy of second‐line pembrolizumab treatment in urothelial cancer regardless of the pre‐chemo NLR. Cancer Immunol. Immunother. 2022; 71: 461–71. - PMC - PubMed